Teva Pharmaceutical Industries Limited
Price Action
Technical Summary
EMERGING TRENDTeva Pharmaceutical Industries Limited is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 86), indicating clear outperformance against the broad market. Earnings growth of 72% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $32.61 | +11.43% | ABOVE |
| 50 SMA | $31.36 | +15.85% | ABOVE |
| 100 SMA | $31.96 | +13.69% | ABOVE |
| 150 SMA | $28.94 | +25.54% | ABOVE |
| 200 SMA | $26.17 | +38.83% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TEVA in an uptrend right now?
TEVA has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is TEVA overbought or oversold?
TEVA's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is TEVA outperforming the market?
TEVA has a Relative Strength (RS) Rating of 86 out of 99. Yes, TEVA is a market leader, outperforming 86% of all stocks over the past 12 months.
Where is TEVA in its 52-week range?
TEVA is trading at $36.34, which is 97% of its 52-week high ($37.35) and 95% above its 52-week low ($14.99).
How volatile is TEVA?
TEVA has a Beta of 1.13 and 52-week volatility of 41%. It's more volatile than the S&P 500 - expect bigger swings.